Detailed Information on Publication Record
2004
Big endothelin in chronic heart failure:marker of disease severity or genetic determination?
ŠPINAROVÁ, Lenka, Jindřich ŠPINAR, Anna VAŠKŮ, Monika GOLDBERGOVÁ, Ondřej LUDKA et. al.Basic information
Original name
Big endothelin in chronic heart failure:marker of disease severity or genetic determination?
Name in Czech
Big endotelin u chronického srdečního selhání:ukazatel tíže onemocnění nebo genetická determinace?
Authors
ŠPINAROVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Anna VAŠKŮ (203 Czech Republic, belonging to the institution), Monika GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Jiří TOMAN (203 Czech Republic), Jiří VÍTOVEC (203 Czech Republic, belonging to the institution), Marie TOMANDLOVÁ (203 Czech Republic, belonging to the institution) and Josef TOMANDL (203 Czech Republic, belonging to the institution)
Edition
International Journal of Cardiology, Ireland, Elsevier, 2004, 0167-5273
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.095
RIV identification code
RIV/00216224:14110/04:00012156
Organization unit
Faculty of Medicine
UT WoS
000188927500011
Keywords in English
Big endothelin; genetic; chronic heart failure; polymorphism
Změněno: 6/6/2012 08:35, doc. RNDr. Josef Tomandl, Ph.D.
V originále
The first objective of the study was to compare the levels of big endothelin and endothelin-1 and other noninvasive parameters used for evaluation of disease severity in patients with stable chronic heart failure (CHF). Endothelin-1 and big endothelin plasma concentrations were measured in 124 chronic heart failure patients. The second objective of the study was to prove an association between endothelin-1 and big endothelin plasma levels and two frequent polymorphisms in the endothelin-1 coding gene (6p21-23) -3A/-4A and G (8002) A in patients with chronic heart failure. Thirdly, we tried to associate other noninvasive parameters of CHF, especially cardiothoracic index (CTI), NYHA classification, signs of pulmonary congestion (PC) and ejection fraction (EF) with determined genotypes of the two ET-1 polymorphic variants. There were significant differences between big endothelin levels in NYHA II versus IV (P<0.001) and NYHA III versus IV (P<0.001) and endothelin-1 in NYHA II versus IV (P<0.001) and NYHA III versus IV (P<0.001). No associations between plasma levels of endothelin-1 and big endothelin and polymorphisms G (8002) A and -3A/-4A in gene coding endothelin-1 were found. In patients with CHF with CTI above 60% the number of carriers of genotypes with ET-1 8002A (AA and AG genotypes) increases. Concerning on the -3A/-4A ET-1 polymorphism, we observed a significant difference in genotype distribution as well as in allelic frequency in the group of patients with CTI above 60% between patients without and with pulmonary congestion. The allelic frequency of 3A allele is twice elevated in the patients with pulmonary congestion (37.8 vs. 78.1%, respectively).
In Czech
Big endotelin u chronického srdečního selhání: ukazatel tíže onemocnění nebo genetická determinace .
Links
| NA7360, research and development project |
|